Seizure Control Outcomes following Resection of Cortical Dysplasia in Patients with DEPDC5 Variants: A Systematic Review and Individual Patient Data Analysis

Abstract

There is insufficient evidence regarding the efficacy of epilepsy surgery in patients with pharmacoresistant focal epilepsy and coexistent DEPDC5 (dishevelled EGL-10 and pleckstrin domain-containing protein 5) pathogenic (P), likely pathogenic (LP), or variance of unknown significance (VUS) variants. To conduct a systematic review on the literature regarding the use and efficacy of epilepsy surgery as an intervention for patients with DEPDC5 variants who have pharmacoresistant epilepsy. A systematic review of the current literature published regarding the outcomes of epilepsy surgery for patients with DEPDC5 variants was conducted. Demographics and individual patient data were recorded and analyzed. Subsequent statistical analysis was performed to assess significance of the findings. A total of eight articles comprising 44 DEPDC5 patients with genetic variants undergoing surgery were included in this study. The articles primarily originated in high-income countries (5/8, 62.5%). The average age of the subjects was 10.06 ± 9.41 years old at the time of study. The most common form of epilepsy surgery was focal resection (38/44, 86.4%). Thirty-seven of the 40 patients (37/40, 92.5%) with reported seizure frequency results had improvement. Twenty-nine out of 38 patients (29/38, 78.4%) undergoing focal resection achieved Engel Score I postoperatively, and two out of four patients achieved International League Against Epilepsy I (50%). Epilepsy surgery is effective in patients with pharmacoresistant focal epilepsy and coexistent DEPDC5 P, LP, or VUS variants.

Keywords

DEPDC5 - epilepsy - surgery

Publication History

Received: 06 July 2023

Accepted: 16 November 2023

Accepted Manuscript online:
20 November 2023

Article published online:
23 December 2023

• References

• 1 Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy—United States, 2015. MMWR 2017; 66: 821-825
• 2 Sultana B, Panzini MA, Carpentier AV. et al. Incidence and prevalence of drug-resistant epilepsy a systematic review and meta-analysis. Neurology 2021; 96 (17) 805-817
• 3 Cohen NT, Chang P, You X. et al. Prevalence and risk factors for pharmacoresistance in children with focal cortical dysplasia-related epilepsy. Neurology 2022; 99 (18) e2006-e2013
• 4 Baud MO, Perneger T, Racz A. et al. European trends in epilepsy surgery. Neurology 2018; 91: e96-e106
• 5 Hemb M, Velasco TR, Parnes MS. et al. Improved outcomes in pediatric epilepsy surgery: the UCLA experience. Neurology 2010; 74: 1768-1775
• 6 Wagstyl K, Whitaker K, Raznahan A. et al. Atlas of lesion locations and postsurgical seizure freedom in focal cortical dysplasia: a MELD study. Epilepsia 2022; 63 (01) 61-74 . Erratum in: Epilepsia 2022;63(4):1018
• 7 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021; 88: 105906
• 8 Page MJ, Moher D, Bossuyt PM. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 372: n160
• 9 Shlobin NA, Moher D. Commentary: preferred reporting items for systematic reviews and meta-analyses 2020 statement: what neurosurgeons should know. Neurosurgery 2021; 89 (05) E267-E268
• 10 Stewart LA, Clarke M, Rovers M. et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA 2015; 313 (16) 1657-1665
• 11 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev 2016; 5: 210
• 12 Guyatt GH, Oxman AD, Vist GE. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336 (7650) 924-926
• 13 Sterne JA, Hernán MA, Reeves BC. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919
• 14 Scheffer IE, Berkovic S, Capovilla G. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for classification and terminology. Epilepsia 2017; 58 (04) 512-521
• 15 Baulac S, Ishida S, Marsan E. et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol 2015; 77 (04) 675-683
• 16 Ying Z, Wang I, Blümcke I. et al. A comprehensive clinico-pathological and genetic evaluation of bottom-of-sulcus focal cortical dysplasia in patients with difficult-to-localize focal epilepsy. Epileptic Disord 2019; 21 (01) 65-77
• 17 Garcia CAB, Carvalho SCS, Yang X. et al. mTOR pathway somatic variants and the molecular pathogenesis of hemimegalencephaly. Epilepsia Open 2020; 5 (01) 97-106
• 18 Benova B, Sanders MWCB, Uhrova-Meszarosova A. et al. GATOR1-related focal cortical dysplasia in epilepsy surgery patients and their families: a possible gradient in severity?. Eur J Paediatr Neurol 2021; 30: 88-96
• 19 Baldassari S, Picard F, Verbeek NE. et al. The landscape of epilepsy-related GATOR1 variants. Genet Med 2019; 21 (02) 398-408 . Erratum in: Genet Med 2018
• 20 Scerri T, Riseley JR, Gillies G. et al. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann Clin Transl Neurol 2015; 2 (05) 575-580
• 21 Sahly AN, Whitney R, Costain G. et al. Epilepsy surgery outcomes in patients with GATOR1 gene complex variants: report of new cases and review of literature. Seizure 2023; 107: 13-20
• 22 Wang H, Liu W, Zhang Y, Liu Q, Cai L, Jiang Y. Seizure features and outcomes in 50 children with GATOR1 variants: a retrospective study, more favorable for epilepsy surgery. Epilepsia Open 2023; 8 (03) 969-979
• 23 Stevelink R, Sanders MW, Tuinman MP. et al. Epilepsy surgery for patients with genetic refractory epilepsy: a systematic review. Epileptic Disord 2018; 20: 99-115
• 24 Kang HJ, Kim DS, Kim SH. et al. Epilepsy with SLC35A2 brain somatic mutations in mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE). Ann Child Neurol. 2022; 30 (03) 88-94
• 25 Barba C, Blumcke I, Winawer MR. et al. SLC35A2 Study Group. Clinical features, neuropathology, and surgical outcome in patients with refractory epilepsy and brain somatic variants in the SLC35A2 gene. Neurology 2023; 100 (05) e528-e542
• 26 Arya R, Mangano FT, Horn PS, Holland KD, Rose DF, Glauser TA. Adverse events related to extraoperative invasive EEG monitoring with subdural grid electrodes: a systematic review and meta-analysis. Epilepsia 2013; 54: 828-839
• 27 Schmidt RF, Wu C, Lang MJ. et al. Complications of subdural and depth electrodes in 269 patients undergoing 317 procedures for invasive monitoring in epilepsy. Epilepsia 2016; 57: 1697-1708
• 28 Vadera S, Jehi L, Gonzalez-Martinez J, Bingaman W. Safety and long-term seizure-free outcomes of subdural grid placement in patients with a history of prior craniotomy. Neurosurgery 2013; 73: 395-400
• 29 Sacino MF, Huang SS, Schreiber J, Gaillard WD, Oluigbo CO. Is the use of stereotactic electroencephalography safe and effective in children? A meta-analysis of the use of stereotactic electroencephalography in comparison to subdural grids for invasive epilepsy monitoring in pediatric subjects. Neurosurgery 2019; 84: 1190-1200
• 30 Onal C, Otsubo H, Araki T. et al. Complications of invasive subdural grid monitoring in children with epilepsy. J Neurosurg 2003; 98: 1017-1026
• 31 Cardinale F, Lo Russo G. Stereo-electroencephalography safety and effectiveness: some more reasons in favor of epilepsy surgery. Epilepsia 2013; 54: 1505-1506
• 32 Cardinale F, Casaceli G, Raneri F, Miller J, Lo Russo G. Implantation of stereoelectroencephalography electrodes: a systematic review. J Clin Neurophysiol 2016; 33: 490-502
• 33 Hader WJ, Tellez-Zenteno J, Metcalfe A. et al. Complications of epilepsy surgery: a systematic review of focal surgical resections and invasive EEG monitoring. Epilepsia 2013; 54 (05) 840-847
• 34 Hsieh JK, Pucci FG, Sundar SJ. et al. Beyond seizure freedom: dissecting long-term seizure control after surgical resection for drug-resistant epilepsy. Epilepsia 2023; 64 (01) 103-113
• 35 Chassoux F, Rodrigo S, Semah F. et al. FDG-PET improves surgical outcome in negative MRI Taylor-type focal cortical dysplasias. Neurology 2010; 75 (24) 2168-2175
• 36 Chassoux F, Landré E, Mellerio C. et al. Type II focal cortical dysplasia: electroclinical phenotype and surgical outcome related to imaging. Epilepsia 2012; 53 (02) 349-358
• 37 Capraz IY, Kurt G, Akdemir Ö. et al. Surgical outcome in patients with MRI-negative, PET-positive temporal lobe epilepsy. Seizure 2015; 29: 63-68